[
  {
    "ts": null,
    "headline": "Why the Market Dipped But Eli Lilly (LLY) Gained Today",
    "summary": "In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=38903c58145af9bc1176ef53a48f522e22acb170a9ac36dd7ccdf1de97d13911",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736289921,
      "headline": "Why the Market Dipped But Eli Lilly (LLY) Gained Today",
      "id": 132310858,
      "image": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=38903c58145af9bc1176ef53a48f522e22acb170a9ac36dd7ccdf1de97d13911"
    }
  },
  {
    "ts": null,
    "headline": "What Trump’s Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk",
    "summary": "What Trump’s Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk",
    "url": "https://finnhub.io/api/news?id=0b7004981f16bab3a475b7340e6ceab38f24a421d2c9f8e98e767a2af7d7b87f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736271120,
      "headline": "What Trump’s Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk",
      "id": 132321543,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "What Trump’s Denmark Tariff Threat Means for Ozempic Drugmaker Novo Nordisk",
      "url": "https://finnhub.io/api/news?id=0b7004981f16bab3a475b7340e6ceab38f24a421d2c9f8e98e767a2af7d7b87f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
    "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=dd178f3e9055bdd6e1676313c2e053792ca9170e64c327c0fceca621be3ea27b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736267640,
      "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
      "id": 132321544,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=dd178f3e9055bdd6e1676313c2e053792ca9170e64c327c0fceca621be3ea27b"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to participate in J.P. Morgan Healthcare Conference",
    "summary": "Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time.",
    "url": "https://finnhub.io/api/news?id=78d15c2f9cc3e7b3ced65cb96b75f597dd9790d15c5021bbb909edb3d3c50b94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736262000,
      "headline": "Lilly to participate in J.P. Morgan Healthcare Conference",
      "id": 132310859,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time.",
      "url": "https://finnhub.io/api/news?id=78d15c2f9cc3e7b3ced65cb96b75f597dd9790d15c5021bbb909edb3d3c50b94"
    }
  },
  {
    "ts": null,
    "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
    "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
    "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736249479,
      "headline": "Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)",
      "id": 132302431,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects for 2025.",
      "url": "https://finnhub.io/api/news?id=f1588fec1459d5307c6fb14d2a4090f5abed15b46fc8ab0d4ba8d1e2024cdad0"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Large Cap Growth Strategy Q4 2024 Commentary",
    "summary": "In a period of momentum-driven returns and bullish investor sentiment sparked by the re-election of Donald Trump, the more defensively positioned Strategy underperformed.",
    "url": "https://finnhub.io/api/news?id=e1daac718535fa1c98749ddca4d274be967f91e2f351129eb0739e003c46acc2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736245200,
      "headline": "ClearBridge Large Cap Growth Strategy Q4 2024 Commentary",
      "id": 132301203,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/117247268/image_117247268.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "In a period of momentum-driven returns and bullish investor sentiment sparked by the re-election of Donald Trump, the more defensively positioned Strategy underperformed.",
      "url": "https://finnhub.io/api/news?id=e1daac718535fa1c98749ddca4d274be967f91e2f351129eb0739e003c46acc2"
    }
  },
  {
    "ts": null,
    "headline": "My Recommended Portfolio Picks For 2025",
    "summary": "Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American indexes.",
    "url": "https://finnhub.io/api/news?id=a3f60acf664ef01e54d5a80066888b177174e542920609c23a67b91eaea61d0d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736240400,
      "headline": "My Recommended Portfolio Picks For 2025",
      "id": 132300260,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166683180/image_2166683180.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American indexes.",
      "url": "https://finnhub.io/api/news?id=a3f60acf664ef01e54d5a80066888b177174e542920609c23a67b91eaea61d0d"
    }
  }
]